Targeting chronic lymphocytic leukemia (CLL): Approaches to care at different stages of the disease
Activity Description / Statement of Need:
In this online, self-learning activity:
Chronic lymphocytic leukemia (CLL) is a diverse group of hematologic cancers in which B-cells accumulate in the blood, bone marrow, and lymphatic tissue, constituting as absolute lymphocytosis of mature-appearing lymphocytes with an appropriate immunophenotype. CLL is an indolent disease and often goes undetected for some time. Patients may present clinically with a range of constitutional symptoms usually range from lymphadenopathy, night sweats, weight loss, weakness, and fever. Staging systems take into account a variety of factors, including lymphadenopathy, splenomegaly, hepatomegaly, and the presence and severity of cytopenias, while a patient’s prognosis is impacted by gene mutation status and cytogenetic and chromosomal abnormalities. Both the presentation and progression of CLL vary between patients, although patients diagnosed in advanced or high-risk stages of the disease have a median survival of less than four years.
Target Audience:
The following HCPs: Medical oncologists and hematologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and other healthcare professionals who commonly encounter patients with CLL.
Cost: Free
View Offer chevron_rightDetails
Activity Description / Statement of Need:
In this online, self-learning activity:
Chronic lymphocytic leukemia (CLL) is a diverse group of hematologic cancers in which B-cells accumulate in the blood, bone marrow, and lymphatic tissue, constituting as absolute lymphocytosis of mature-appearing lymphocytes with an appropriate immunophenotype. CLL is an indolent disease and often goes undetected for some time. Patients may present clinically with a range of constitutional symptoms usually range from lymphadenopathy, night sweats, weight loss, weakness, and fever. Staging systems take into account a variety of factors, including lymphadenopathy, splenomegaly, hepatomegaly, and the presence and severity of cytopenias, while a patient’s prognosis is impacted by gene mutation status and cytogenetic and chromosomal abnormalities. Both the presentation and progression of CLL vary between patients, although patients diagnosed in advanced or high-risk stages of the disease have a median survival of less than four years.
Target Audience:
The following HCPs: Medical oncologists and hematologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and other healthcare professionals who commonly encounter patients with CLL.